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Abstract. Mutations in the ras family genes (K-ras mainly) 
represent a common event in lung tumorigenesis which is 
frequently associated with poor clinical outcome. In order to 
investigate whether K-ras mutations are detectable in 
cytological material obtained from patients with lung cancer, 
37 cytological specimens (16 fine needle aspiration and 21 
bronchoscopy) were assessed for codon 12 point mutations in 
the H-, K- and N-ras genes by combined polymerase chain 
reaction-restriction fragment length polymorphism. K-ras 
codon 12 point mutations were found in 8 out of 37 (22%) 
specimens while no mutations were found in the Η-ras and 
N-ras genes. Mutations were found in 27% (3 out of 11) of 
adenocarcinomas while in squamous cell carcinomas the 
incidence of mutations was 18% (3 out of 17). In addition, a 
K-ras codon 12 point mutation was found in one (12%) 
among 8 small cell carcinomas and in the only Hodgkin's 
lymphoma with metastasis in the lung. Our results are in 
agreement with previous results that recognise high incidence 
of K-ras activation in lung carcinomas, and indicate that 
detection of mutant ras alleles is possible in cytological 
material. 
Introduction 
The development of neoplasia requires specific genetic 
events targeting the activation of oncogenes and the 
inactivation of tumour suppressor genes (TSGs) (1). The ras 
family genes that encode for small GTPases of the plasma 
membrane, are frequently found activated in various human 
tumours. Activation of the ras family genes usually occurs 
by point mutations at codons 12, 13 and 61, abolishing from 
the mutant protein the property to exchange GTP with GDP 
and to remain constantly activated (2). 
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Activated members of the ras family have been detected 
in approximately 90% of pancreatic and 40% of colorectal 
cancers (3). In lung tumours 30% of the specimens, mainly 
adenocarcinomas, harbour ras mutations. The mutations 
usually affect the K-ras proto-oncogene, but Η-ras and N-ras 
genes have also been found to harbour activating point 
mutations. Furthermore, lung tumours harbouring an 
activated member of the ras family, are characterised by poor 
clinical outcome, indicating an important role for the ras 
genes in the development of the disease (4-8). 
A major problem in lung tumorigenesis is the late stage of 
the disease in which the tumour is detectable. The detection 
of particular molecular alterations, highly associated with the 
development of the disease, could serve as a molecular 
marker for the development of the tumour and help in the 
early detection of cancer. 
In the present study, we evaluated the incidence of 
activated members of the ras family in cytological material 
obtained from patients with lung cancer. The detection of the 
mutant ras alleles was performed by a sensitive polymerase 
chain reaction-restriction fragment length polymorphism 
(PCR-RFLP) assay. 
Materials and methods 
Specimens. 37 cytological specimens (16 fine needle 
aspiration (FNA) and 21 bronchoscopy), consisting of 11 
adenocarcinomas, 17 squamous cell carcinomas (SCC), 8 
small cell carcinomas and one Hodgkin's lymphoma with 
metastasis in lung were obtained from the Department of 
Cytology, General Hospital of Nikeas, Pireas, Greece. 
DNA extraction. Specimens were washed with IX PBS buffer 
and DNA was extracted following standard proteinase Κ and 
phenol-chloroform extraction (9). 
Polymerase chain reaction. Approximately 300 ng of 
genomic DNA was amplified by the PCR in a 50 μΐ reaction 
volume containing 500 μΜ dNTPs, 30 pM of each forward 
and reverse primer (10), 0.5 U of Taq DNA polymerase and 
5 μΐ of 10X buffer (670 mM Tris.HCl, pH 8.5; 166 mM 
ammonium sulphate; 67 mM magnesium chloride; 1.7 mg/ml 
BSA; 100 μΜ, ß-mercaptoethanol and 1% (w/v) Triton 
X-100). PCR programs consisted of 95°C for 4 min and 35 
cycles of 95°C, 57°C and 72°C for 40 sec each step. 
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Detection of ras mutations at codon 12 by restriction 
fragment length polymorphism (RFLP). PCR amplification of 
the ras genes surrounding codon 12 was performed as 
described above. 30 μΐ of the PCR product was digested 
overnight with 20 U of the restriction endonucleases Msp\ 
(Η-ras) and BstNl (K-ras and N-ras) in conditions 
recommended by the suppliers, electrophoresed in a 2% 
agarose gel (or 6% Polyacrylamide gel for the N-ras codon 12) 
and stained with ethidium bromide. 
Results 
In the present study we employed a combined PCR-RFLP 
assay in order to detect point mutations at codon 12 of H-, K-
and N-ras genes in cytological material from patients with 
lung cancer (11 adenocarcinomas, 17 squamous cell 
carcinomas (SCC), 8 small cell carcinoma and one Hodgkin's 
lymphoma with metastasis in the lung). Our analysis revealed 
that 8 among 37 (22%) specimens harboured a mutation at 
the K-ras gene (Table I, Fig. 1) while no mutations were 
found in the W-ras and N-ras genes, confirming previous 
reports (4-8) of higher incidence of mutations in lung cancer 
occuring in the K-ras gene. 
The higher incidence of mutations was found in 
adenocarcinomas (3 out of 11, 27%). In SCC 3 out of 17 
(18%) specimens were found positive for a K-ras point 
mutation. In addition, a K-ras codon 12 point mutation was 
found in a Hodgkin's lymphoma with metastasis in the lung 
(Table II). One (12.5%) mutation was also found in 8 small 
cell carcinomas. No association was found between the 
presence of mutation and the stage of the disease (Table III). 
As regards the cytological method of tissue extraction, 5 
(31%) FNA samples among 16 were found positive for a 
K-ras mutation while only 3 (14%) among 21 bronchoscopy 
samples were positive for a K-ras mutation (Table IV). 
Discussion 
Activating mutations in the ras family genes represent a 
relatively common feature of lung tumours. We report that 
detection of activated ras alleles is possible in cytological 
Figure 1. Detection of K-ras codon 12 point mutations by a combined PCR-
RFLP assay. Lane 1, DNA from the cell line SW 480 (mutant for K-ras 
codon 12); lanes 2-5, normal samples; lanes 6,7, samples with a mutation at 
K-ras codon 12; M. pUC 18/HaeIII. 
Table I. Codon 12 point mutations in the ras family genes in 
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aAC, adenocarcinoma; SCC, squamous cell carcinoma. bB, 
bronchoscopy; FNA, fine needle aspiration. 
material from patients with lung cancer. This could be of 
considerable importance in the clinical practice because the 
presence of mutant ras alleles is associated with poor 
prognosis in lung tumours (4-8). 
The higher incidence of ras mutations was found in 
adenocarcinomas (3/11, 27%). Significant incidence of 
mutations was also found in SCC (3/17, 18%). Although the 
incidence of mutations reported in this study is lower than 
those reported by other investigators, generally our data are 
in agreement with previous findings. Suzuki et al (5) and 
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Table II. K-ras codon 12 point mutations in association with 
the cytological diagnosis. 
Cytological type No. of samples K-ras mutations (%) 
Adenocarcinoma 11 3 (27) 
S C O 17 3(18) 
Small cell 8 1(13) 
Hodgkin's lymphoma 1 1 
Total 37 8 (22) 
aSCC, squamous cell carcinoma. 
Table III. K-ras codon 12 point mutations in association with 
the stage of the disease. 
Stage No. of samples K-ras mutations (%) 
Stage I+II 12 3(25) 
Stage III 25 5 (20) 
Table IV. Codon 12 point mutations in the K-ras gene in 
association with the cytological method. 
Cytological method No. of samples K-ras mutations (%) 
FNAa 16 5(31) 
Bronchoscopy 21 3(14) 
'FNA, fine needle aspiration. 
Rodenhuis and Slebos (8) detected mutations at K-ras codon 
12 in approx imate ly 3 0 % of lung tumours , while the 
incidence of Η-ras and N-ras point mutations was limited to 
1.5% and 4.5% respectively. The majority of the mutations 
were found in a d e n o c a r c i n o m a s , however, act ivat ing 
mutations were also detected in large cell carcinomas (LCC, 
14%) and SCC (5.5%) (5). The high incidence of K-ras 
m u t a t i o n s in a d e n o c a r c i n o m a s as c o m p a r e d to other 
histological entities of lung tumours (such as LCC and SCC), 
was not confirmed by a Spanish group (11) who demonstrated 
the presence of activating mutations of the K-ras gene in 2 1 % 
of the SCC, while in adenocarcinomas the incidence of 
mutations was 14% of the specimens. The discrepancy may 
be due to the different epidemiological factors and is 
common to studies on the ras genes (9,12). 
A major problem in the detection of mutant ras alleles in 
cytological material is the presence of DNA from the 
adjacent normal tissue, in significant ratio as compared to the 
DNA from the tumour cells. In the case of FNA, normal 
DNA is derived from the peripheral blood which is present 
during the aspiration, while in the case of bronchoscopy 
normal epithelial cells may be present. In the case of a 
heterozygous mutation, a ratio of 1:1 between tumour versus 
normal cells results in a ratio of 1:3 between mutant versus 
normal ras alleles. In this case, a competition occurs during 
the in vitro ampl i f icat ion r e a c t i o n , which resul t s in 
significant decrease of the signal derived by the mutant 
allele. This may explain the slightly lower incidence of 
mutations reported in our study, as compared to that reported 
by others. However, the present study indicates that the 
detect ion of mutant K-ras al le les is possible in DNA 
extracted from cytological material and can be successfully 
applied in the clinical practice, at least in a subset of cases. 
Most of the mutations (Table IV) were detected in the FNA 
material, indicating that this is the more suitable technique 
for the detection of ras mutations. 
Future investigations, aiming to increase the specificity of 
the cytological techniques and the sensitivity of the PCR 
amplification should be performed in order to make possible 
the application of molecular techniques in routine clinical 
practice. 
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